Items

• Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  C. Hee Suh, A. Berrocal Kasay, E. Chalouhi El-Khouri, P. Miranda, LJ. Božić, S. Jeka, P. Hrycaj, D. Rekalov, P. Wiland, A. Krause, I. Szombati, A. Mihailova, I. Hospodarskyy, M. Piotrowski, S. Ryul Kwon, E. Young Lee, D. Hyun Yoo, W. Park, S. Cheol Shim, S. Joon Lee, T. S. Kwon, Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, pp. 100 - 101, Sep, 2016

• Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  W. Park, LJ. Božić, D. Milakovic, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodriguez, P. Wiland, S. Jeka, J. Chavez-Corrales, O. Garmish, T. Linde, D. Rekalov, P. Hrycaj, A. Krause, N. Fomina, O. Piura, M. Abello-Banfi, C. Hee Suh, S. Cheol Shim, S. Joon Lee, S. Young Lee, S. Hwan Kim, D. Hyun Yoo, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, pp. 100 - 101, Sep, 2016